The EMA's Emergency Task Force (ETF) has evaluated data on the use of the monkeypox vaccine Imvanex as an intradermal injection (administered just below the top layer of the skin).
The vaccine was licensed only for use as a subcutaneous injection (injection under the skin). However, when administered intradermally, a smaller dose of the vaccine may be used. Given the currently limited availability of the vaccine, this means that more people may be vaccinated.
ETF reviewed data from a clinical trial involving approximately 500 adults, which compared the vaccine administered either intradermally or subcutaneously as 2 doses with a 4-week interval between each dose. Subjects who received the vaccine intradermally received one-fifth (0.1 ml) of the subcutaneous dose (0.5 ml), but produced similar levels of antibodies to subjects who received the higher subcutaneous dose.
The ETF warned that there was a higher risk of local reactions (e.g., longer-lasting redness and thickening or discoloration of the skin) following intradermal injections.
The ETF noted that no information is available on the maximum number of 0.1 ml doses that can be extracted from the licensed product (0.5 ml suspension) and recommended the use of low dead volume syringes to optimise the number of doses that can be extracted. The ETF also stressed the importance of proper administration of intradermal injections, recommending that only healthcare professionals experienced in administering intradermal injections should administer the vaccine in this way. Further information for healthcare professionals is included in the ETF statement.
Taking all these parameters into account, national competent authorities may decide as a temporary measure to use Imvanex vaccine as an intradermal injection at a lower dose to protect persons at risk during the current outbreak of smallpox in monkeys, as the supply of the vaccine remains limited.
Imvanex was first licensed in the year 2013 under the 'exceptional circumstances' procedure for protection against smallpox. Following an application to extend its use, on 22 July 2022 the vaccine was licensed for protection against monkeypox disease.
The ETF recommendation has been issued to address the monkeypox outbreak in multiple EU countries as part of its public health emergency preparedness activities, which include providing recommendations to support regulatory activities and product-related assessments.
More about Imvanex
Imvanex prepares the body to defend against infection by variola (smallpox), monkeypox and damalitis viruses. It contains an attenuated form of the damalitis virus called "modified malaria virus Ankara (MVVA)", which is closely related to the smallpox and monkeypox viruses, but does not cause disease in humans and cannot replicate in human cells. Because of the similarity between the virus in the vaccine and the aforementioned viruses, antibodies produced against it are expected to protect against monkeypox, smallpox and damalitis.
When a person is given the vaccine, the immune system recognizes the virus in the vaccine as "foreign" and produces antibodies against the virus. When the person subsequently comes into contact with similar viruses, these antibodies along with other components of the immune system will be able to kill these viruses and help protect against the disease.
The marketing authorisation holder of Imvanex is Bavarian Nordic A/S.
More about monkeypox
Monkeypox is a rare disease caused by infection with the monkeypox virus, with symptoms similar to smallpox. Monkeypox begins with fever, headache, muscle aches, exhaustion and lymphadenopathy. A rash usually appears one to three days after the onset of fever, starting on the face and spreading to other parts of the body, including the hands and feet.
Monkeypox can be fatal, but is usually milder than smallpox. It is transmitted to humans from various wild animals, such as rodents and primates, but can also be transmitted between humans after close contact. The current spike in cases reported from May 2022 relates to the first cases recorded outside Africa with no link to endemic areas. On 23 July 2022, the World Health Organization declared the monkeypox outbreak a public health emergency of international concern.
(AF)
Contents of this article including associated images are owned by PIO
Views & opinions expressed are those of the author and/or PIO
Source